Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

[1]  S. Kubicka,et al.  Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Natsugoe,et al.  Increased Slug and decreased E-cadherin expression is related to poor prognosis in patients with gastric cancer , 2011, Gastric Cancer.

[3]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[4]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[5]  M. Shah,et al.  Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  A. Bardelli,et al.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Lordick,et al.  Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) , 2010, British Journal of Cancer.

[8]  A. Bardelli,et al.  Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) , 2009, British Journal of Cancer.

[9]  S. DeMeester.  Epidemiology and biology of esophageal cancer. , 2009, Gastrointestinal cancer research : GCR.

[10]  P. Harari,et al.  Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells , 2009, Clinical Cancer Research.

[11]  Y. Bang,et al.  Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer , 2009, British Journal of Cancer.

[12]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Van Cutsem,et al.  Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study , 2008, Clinical Cancer Research.

[14]  M. Moroni,et al.  EGFR FISH in colorectal cancer: what is the current reality? , 2008, The Lancet. Oncology.

[15]  Xifeng Wu,et al.  Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells , 2008, Clinical Cancer Research.

[16]  R. Langer,et al.  Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer , 2008, Modern Pathology.

[17]  R. Langer,et al.  Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations. , 2008, Cancer research.

[18]  R. Seruca,et al.  Bmc Cancer Epidermal Growth Factor Receptor Structural Alterations in Gastric Cancer , 2022 .

[19]  R. Langer,et al.  Significance of HER2 Low-Level Copy Gain in Barrett's Cancer: Implications for Fluorescence In situ Hybridization Testing in Tissues , 2007, Clinical Cancer Research.

[20]  R. Seruca,et al.  EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. , 2007, Human molecular genetics.

[21]  M. Trivett,et al.  Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer , 2007, Familial Cancer.

[22]  R. Berardi,et al.  Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  J. Minna,et al.  Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. , 2006, Cancer research.

[24]  Bing Yu,et al.  DNA Mutation Detection Using Denaturing High‐Performance Liquid Chromatography (DHPLC) , 1998, Current protocols in human genetics.

[25]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[26]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Höfler,et al.  E-cadherin expression in sporadic gastric cancer from Mexico: exon 8 and 9 deletions are infrequent events associated with poor survival. , 2005, Human pathology.

[28]  H. Höfler,et al.  Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients , 2004, Journal of Medical Genetics.

[29]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[30]  J. Nährig,et al.  Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system , 2004, Modern Pathology.

[31]  Douglas R Lowy,et al.  E‐cadherin‐mediated adhesion inhibits ligand‐dependent activation of diverse receptor tyrosine kinases , 2004, The EMBO journal.

[32]  Suk Woo Nam,et al.  BRAF and KRAS mutations in stomach cancer , 2003, Oncogene.

[33]  Jae-Hyun Park,et al.  Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers , 2003, Human Genetics.

[34]  C. Moskaluk,et al.  Inactivation of the E-Cadherin Gene in Sporadic Diffuse-Type Gastric Cancer , 2001, Modern Pathology.

[35]  H. Höfler,et al.  Sequential Multilocus Fluorescence In Situ Hybridization Can Detect Complex Patterns of Increased Gene Dosage at the Single Cell Level in Tissue Sections , 2001, Laboratory Investigation.

[36]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[37]  H. Höfler,et al.  Her-2/neu Gene Amplification, Elevated mRNA Expression, and Protein Overexpression in the Metaplasia-Dysplasia-Adenocarcinoma Sequence of Barrett’s Esophagus , 2001, Laboratory Investigation.

[38]  C. Caldas,et al.  E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma , 2001, Oncogene.

[39]  H. Höfler,et al.  Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility , 1999, Oncogene.

[40]  G. Berx,et al.  E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[41]  H. Höfler,et al.  Identification of eleven novel tumor‐associated e‐cadherin mutations , 1999, Human mutation.

[42]  Hiroshi Yamamoto,et al.  Amplification of the c-met, c-erbB-2 and Epidermal Growth Factor Receptor Gene in Human Gastric Cancers: Correlation to Clinical Features , 1998, Oncology.

[43]  Heinz Höfler,et al.  Mutations of the human E‐cadherin (CDH1) gene , 1998, Human mutation.

[44]  G. Berx,et al.  E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. , 1996, Oncogene.

[45]  M. Vijver,et al.  E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. , 1995, The EMBO journal.

[46]  H. Höfler,et al.  E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. , 1994, Cancer research.

[47]  A. Berchuck,et al.  Mutations of the E–cadherin gene in human gynecologic cancers , 1994, Nature Genetics.